{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:26:12Z","timestamp":1795195572288,"version":"4.10.3"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.neuroscience.2024.12.029","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:55:29Z","timestamp":1734609329000},"page":"133-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["A review on multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations"],"prefix":"10.1016","volume":"567","author":[{"given":"Syeda","family":"Rida Zainab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Zeb Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Khalid Tipu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryal","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2024.12.029_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577061","article-title":"The role of immune regulatory molecules in multiple sclerosis","volume":"337","author":"Afshar","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1101\/gad.344218.120","article-title":"Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function","volume":"35","author":"Akay","year":"2021","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0015","doi-asserted-by":"crossref","unstructured":"AL GAWWAM, G. & SHARQUIE, I. K. 2017. Serum glutamate is a predictor for the diagnosis of multiple sclerosis. The Scientific World Journal, 2017, 9320802.","DOI":"10.1155\/2017\/9320802"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fncel.2020.00043","article-title":"CD8 T-cell recruitment into the central nervous system of cuprizone-fed mice: relevance to modeling the etiology of multiple sclerosis","volume":"14","author":"Almuslehi","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jneuroim.2018.10.004","article-title":"Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis","volume":"329","author":"Alrouji","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0030","doi-asserted-by":"crossref","unstructured":"ANAND, A. A., KHAN, M., V, M. & KAR, D. 2023. The Molecular Basis of Wnt\/\u03b2\u2010Catenin Signaling Pathways in Neurodegenerative Diseases. International Journal of Cell Biology, 2023, 9296092.","DOI":"10.1155\/2023\/9296092"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00401-012-0953-0","article-title":"Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?","volume":"123","author":"Antel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0166-2236(98)01287-9","article-title":"The role of integrins in immune-mediated diseases of the nervous system","volume":"22","author":"Archelos","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fimmu.2015.00492","article-title":"Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"6","author":"Arellano","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0050","doi-asserted-by":"crossref","unstructured":"ARNETH, B. M. 2019. Impact of B cells to the pathophysiology of multiple sclerosis. Journal of Neuroinflammation, 16, 1-9.","DOI":"10.1186\/s12974-019-1517-1"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0055","unstructured":"ATLAS 2020. The multiple sclerosis internation federation."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/cn300186b","article-title":"A dialogue between the immune system and brain, spoken in the language of serotonin","volume":"4","author":"Baganz","year":"2013","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0065","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.3390\/ijms22168370","article-title":"Reviewing the significance of blood\u2013brain barrier disruption in multiple sclerosis pathology and treatment","volume":"22","author":"Balasa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-023-06618-z","article-title":"Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations","volume":"625","author":"Barrie","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0075","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.1038\/s41598-020-63613-4","article-title":"Cigarette smoking induces human CCR6+ Th17 lymphocytes senescence and VEGF-A secretion","volume":"10","author":"Baskara","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0080","article-title":"Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment","volume":"17","author":"Basoglu","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0085","doi-asserted-by":"crossref","unstructured":"BHAT, M. Y., SOLANKI, H. S., ADVANI, J., KHAN, A. A., KESHAVA PRASAD, T., GOWDA, H., THIYAGARAJAN, S. & CHATTERJEE, A. 2018. Comprehensive network map of interferon gamma signaling. Journal of cell communication and signaling, 12, 745-751.","DOI":"10.1007\/s12079-018-0486-y"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0090","article-title":"Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States","volume":"2017","author":"Bhattacharjee","year":"2017","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0095","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0105","doi-asserted-by":"crossref","unstructured":"BRANDSTADTER, R. & KATZ SAND, I. 2017. The use of natalizumab for multiple sclerosis. Neuropsychiatric disease and treatment, 1691-1702.","DOI":"10.2147\/NDT.S114636"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0110","doi-asserted-by":"crossref","unstructured":"BRAY, S. J. 2006. Notch signalling: a simple pathway becomes complex. Nature reviews Molecular cell biology, 7, 678-689.","DOI":"10.1038\/nrm2009"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0120","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ni.2080","article-title":"The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation","volume":"12","author":"Bulek","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0125","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/carcin\/bgt127","article-title":"The Notch signaling pathway as a mediator of tumor survival","volume":"34","author":"Capaccione","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0130","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41467-019-11139-3","article-title":"Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes","volume":"10","author":"Carlstr\u00f6m","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1469-7580.2008.00984.x","article-title":"Expression and distribution of \u2018high affinity\u2019glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system","volume":"213","author":"Carozzi","year":"2008","journal-title":"J. Anat."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Chataway","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0145","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/659206","article-title":"Chemokines and chemokine receptors in multiple sclerosis","volume":"2014","author":"Cheng","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0150","first-page":"1","article-title":"Rituximab for the treatment of multiple sclerosis: a review","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0155","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/oby.2003.75","article-title":"Plasma leptin, fatty acids, and tumor necrosis factor\u2010receptor and insulin resistance in children","volume":"11","author":"Chu","year":"2003","journal-title":"Obes. Res."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0165","doi-asserted-by":"crossref","unstructured":"CLATCH, R. J., LIPTON, H. L. & MILLER, S. D. 1986. Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. Journal of immunology (Baltimore, Md.: 1950), 136, 920-927.","DOI":"10.4049\/jimmunol.136.3.920"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/biomedicines8070227","article-title":"Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article","volume":"8","author":"Cohan","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clineuro.2004.02.012","article-title":"Non-specific immunosuppressants in the treatment of multiple sclerosis","volume":"106","author":"Confavreux","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0180","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0185","doi-asserted-by":"crossref","unstructured":"CREE, B. A., ARNOLD, D. L., CHATAWAY, J., CHITNIS, T., FOX, R. J., POZO RAMAJO, A., MURPHY, N. & LASSMANN, H. 2021. Secondary progressive multiple sclerosis: new insights. Neurology, 97, 378-388.","DOI":"10.1212\/WNL.0000000000012323"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0190","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.3390\/ijms21239189","article-title":"PTEN and other PtdIns (3, 4, 5) P3 lipid phosphatases in breast cancer","volume":"21","author":"Csolle","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0195","doi-asserted-by":"crossref","unstructured":"CUNILL MONJO, V., MASSOT, M., CLEMENTE, A., CALLES, C., ANDREU, V., N\u00da\u00d1EZ, V., L\u00d3PEZ-G\u00d3MEZ, A., D\u00cdAZ, R. M., JIM\u00c9NEZ, M. D. L. R. & PONS, J. 2018. Relapsing-Remitting Multiple Sclerosis is characterized by a T follicular pro-inflammatory shift, reverted by Dimethyl Fumarate treatment. Frontiers In Immunology, 2018, vol. 9, num. 1097.","DOI":"10.3389\/fimmu.2018.01097"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2021.109088","article-title":"An optimized animal model of lysolecithin induced demyelination in optic nerve; more feasible, more reproducible, promising for studying the progressive forms of multiple sclerosis","volume":"352","author":"Dehghan","year":"2021","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0205","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jneuroim.2017.02.012","article-title":"Theiler's murine encephalomyelitis virus infection of SJL\/J and C57BL\/6J mice: models for multiple sclerosis and epilepsy","volume":"308","author":"Depaula-Silva","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12647","article-title":"A regenerative approach to the treatment of multiple sclerosis","volume":"502","author":"Deshmukh","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0220","article-title":"An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0225","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44702","article-title":"CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes","volume":"8","author":"Dimas","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0230","doi-asserted-by":"crossref","unstructured":"DISANTO, G., M MORAHAN, J. & V RAMAGOPALAN, S. 2012. Multiple sclerosis: risk factors and their interactions. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 11, 545-555.","DOI":"10.2174\/187152712801661266"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0235","doi-asserted-by":"crossref","unstructured":"DOBLE, A. 1996. The pharmacology and mechanism of action of riluzole. Neurology, 47, 233S-241S.","DOI":"10.1212\/WNL.47.6_Suppl_4.233S"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fneur.2015.00052","article-title":"The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders","volume":"6","author":"Dobryakova","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0250","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1007\/s11033-023-08419-z","article-title":"Transforming growth factor \u03b2 (TGF-\u03b2) pathway in the immunopathogenesis of multiple sclerosis (MS); molecular approaches","volume":"50","author":"Esmaeilzadeh","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0255","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/pr.118.015487","article-title":"5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface","volume":"71","author":"Fakhfouri","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116844","article-title":"Safety and efficacy of memantine for multiple sclerosis-related fatigue: a pilot randomized, double-blind placebo-controlled trial","volume":"414","author":"Falsafi","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0265","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1471-4159.2010.06982.x","article-title":"Are current disease\u2010modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?","volume":"115","author":"Farooqi","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0270","unstructured":"FEDERATION, M. I. 2022. Epidermiology [Online]. Available: https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms#about [Accessed 2022]."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta\u2010analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0280","doi-asserted-by":"crossref","unstructured":"FORD, H. 2020. Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine, 20, 380-383.","DOI":"10.7861\/clinmed.2020-0292"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0285","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","article-title":"B cells and multiple sclerosis","volume":"7","author":"Franciotta","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0290","doi-asserted-by":"crossref","unstructured":"FRANKLIN, R. J. 2002. Why does remyelination fail in multiple sclerosis? Nature Reviews Neuroscience, 3, 705-714.","DOI":"10.1038\/nrn917"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0295","doi-asserted-by":"crossref","unstructured":"FROHMAN, E. M., SHAH, A., EGGENBERGER, E., METZ, L., ZIVADINOV, R. & ST\u00dcVE, O. 2007. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics, 4, 618-626.","DOI":"10.1016\/j.nurt.2007.07.008"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0300","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0305","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.2414848","article-title":"Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity","volume":"230","author":"Fujinami","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1129906","article-title":"B cell targeted therapies in inflammatory autoimmune disease of the central nervous system","volume":"14","author":"Furman","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0315","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J. (Yakhteh)"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2572.942X\/2016\/7.1064","article-title":"Obesity and multiple sclerosis susceptibility: a review","volume":"1","author":"Gianfrancesco","year":"2016","journal-title":"J. Neurol. Neuromed."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0325","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0330","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1352458518763094","article-title":"Cytokine signaling in multiple sclerosis: lost in translation","volume":"24","author":"G\u00f6bel","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(01)00330-7","article-title":"Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders","volume":"117","author":"Gold","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0345","doi-asserted-by":"crossref","first-page":"e6613","DOI":"10.1371\/journal.pone.0006613","article-title":"Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2","volume":"4","author":"Gordon","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0350","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0355","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1673-5374.245462","article-title":"The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to: in vivo: imaging","volume":"14","author":"Guan","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-021-02344-z","article-title":"The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey","volume":"21","author":"Gustavsen","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0370","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0375","doi-asserted-by":"crossref","unstructured":"HAMMERSCHMIDT, W. 2015. The epigenetic life cycle of Epstein\u2013Barr virus. Epstein Barr virus volume 1: one herpes virus: many diseases, 103-117.","DOI":"10.1007\/978-3-319-22822-8_6"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0380","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1025944723047","article-title":"\u03b2-Catenin and Tcfs in mammary development and cancer","volume":"8","author":"Hatsell","year":"2003","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0390","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"Hausser-Kinzel","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0395","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"H\u00e4usser-Kinzel","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0405","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.humimm.2010.10.016","article-title":"Expression and functional activity of chemokine receptors in glatiramer acetate\u2013specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate","volume":"72","author":"H\u00f8glund","year":"2011","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5493\/wjem.v4.i3.27","article-title":"Multiple sclerosis and the role of immune cells","volume":"4","author":"H\u00f8glund","year":"2014","journal-title":"World J. Exp. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0415","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2021.109443","article-title":"An optimized and validated protocol for inducing chronic experimental autoimmune encephalomyelitis in C57BL\/6J mice","volume":"367","author":"Huntemann","year":"2022","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0425","doi-asserted-by":"crossref","unstructured":"IACOBAEUS, E., SUGARS, R. V., T\u00d6RNQVIST ANDR\u00c9N, A., ALM, J. J., QIAN, H., FRANTZEN, J., NEWCOMBE, J., ALKASS, K., DRUID, H. & BOTTAI, M. 2017. Dynamic changes in brain mesenchymal perivascular cells associate with multiple sclerosis disease duration, active inflammation, and demyelination. Stem cells translational medicine, 6, 1840-1851.","DOI":"10.1002\/sctm.17-0028"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0430","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0435","doi-asserted-by":"crossref","unstructured":"JELCIC, I., AL NIMER, F., WANG, J., LENTSCH, V., PLANAS, R., JELCIC, I., MADJOVSKI, A., RUHRMANN, S., FAIGLE, W. & FRAUENKNECHT, K. 2018. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell, 175, 85-100. e23.","DOI":"10.1016\/j.cell.2018.08.011"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1442694","article-title":"Global perspectives on the contribution of B cells to multiple sclerosis: an in-depth examination and evaluation","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0445","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3389\/fimmu.2018.02198","article-title":"Epstein Barr virus interleukin 10 suppresses anti-inflammatory phenotype in human monocytes","volume":"9","author":"Jog","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102332","article-title":"Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model","volume":"106","author":"Jog","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0455","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fgene.2012.00311","article-title":"MicroRNA dysregulation in multiple sclerosis","volume":"3","author":"Jr","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0460","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2007.09.007","article-title":"Overcoming failure to repair demyelination in EAE: \u03b3-secretase inhibition of Notch signaling","volume":"265","author":"Jurynczyk","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.08.010","article-title":"Notch: a new player in MS mechanisms","volume":"218","author":"Jury\u0144czyk","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0470","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein\u2013Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0475","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2343","article-title":"Immunological complications of obesity","volume":"13","author":"Kanneganti","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0480","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0485","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-\u03baB by toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0490","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0495","doi-asserted-by":"crossref","unstructured":"KIESEIER, B. C. 2011. The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis. CNS drugs, 25, 491-502.","DOI":"10.2165\/11591110-000000000-00000"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0500","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4049\/jimmunol.177.1.566","article-title":"IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis","volume":"177","author":"Komiyama","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0505","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0510","doi-asserted-by":"crossref","unstructured":"KOPAN, R. 2012. Notch signaling. Cold Spring Harbor perspectives in biology, 4, a011213.","DOI":"10.1101\/cshperspect.a011213"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0515","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1515\/revneuro-2012-0062","article-title":"Multiple sclerosis and glutamate excitotoxicity","volume":"24","author":"Kostic","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0520","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clineuro.2013.12.021","article-title":"Mechanistic insights into corticosteroids in multiple sclerosis: War horse or chameleon?\u2606","volume":"119","author":"Krieger","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0898-6568(02)00083-9","article-title":"CD40 and its viral mimic, LMP1: similar means to different ends","volume":"15","author":"Lam","year":"2003","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0530","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology"},{"issue":"1383\u20131396","key":"10.1016\/j.neuroscience.2024.12.029_b0535","first-page":"e12","article-title":"Epsin-dependent ligand endocytosis activates Notch by force","volume":"171","author":"Langridge","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0540","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135245859700300213","article-title":"Remyelination in multiple sclerosis","volume":"3","author":"Lassmann","year":"1997","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0545","doi-asserted-by":"crossref","unstructured":"LASSMANN, H. 2019. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Frontiers in immunology, 9, 3116.","DOI":"10.3389\/fimmu.2018.03116"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0550","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/eji.201646716","article-title":"TGF\u2010\u03b2 regulation of encephalitogenic and regulatory T cells in multiple sclerosis","volume":"47","author":"Lee","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0555","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1172\/JCI31254","article-title":"A little stress is good: IFN-\u03b3, demyelination, and multiple sclerosis","volume":"117","author":"Lees","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0560","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fnmol.2016.00084","article-title":"NF-\u03baB pathways in the pathogenesis of multiple sclerosis and the therapeutic implications","volume":"9","author":"Leibowitz","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0565","doi-asserted-by":"crossref","first-page":"E1168","DOI":"10.1073\/pnas.1609905114","article-title":"Endothelial Wnt\/\u03b2-catenin signaling reduces immune cell infiltration in multiple sclerosis","volume":"114","author":"Lengfeld","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0570","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00702-016-1640-4","article-title":"Dopamine, T cells and multiple sclerosis (MS)","volume":"124","author":"Levite","year":"2017","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0575","doi-asserted-by":"crossref","unstructured":"LEVITE, M. 2017. Glutamate, T cells and multiple sclerosis. Journal of Neural Transmission, 124, 775-798.","DOI":"10.1007\/s00702-016-1661-z"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0580","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0585","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0590","doi-asserted-by":"crossref","unstructured":"LORUSSO, P. M. 2016. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. Journal of clinical oncology, 34, 3803-3815.","DOI":"10.1200\/JCO.2014.59.0018"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0595","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.3390\/ijms241914447","article-title":"Changes in the expression of TGF-beta regulatory pathway genes induced by vitamin D in patients with relapsing-remitting multiple sclerosis","volume":"24","author":"Lozano-Ros","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0600","doi-asserted-by":"crossref","unstructured":"LUBLIN, F. D., COETZEE, T., COHEN, J. A., MARRIE, R. A., THOMPSON, A. J. & MS, I. A. C. O. C. T. I. 2020. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology, 94, 1088-1092.","DOI":"10.1212\/WNL.0000000000009636"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0605","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0610","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0615","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1038\/s41598-018-22047-9","article-title":"Absence of claudin 11 in CNS myelin perturbs behavior and neurotransmitter levels in mice","volume":"8","author":"Maheras","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840158","article-title":"Smoking attributable risk in multiple sclerosis","volume":"13","author":"Manouchehrinia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0625","article-title":"Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI","volume":"28","author":"Mart\u00ednez-Heras","year":"2020","journal-title":"NeuroImage: Clinical"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0630","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/glia.20275","article-title":"Glutamate\u2010mediated glial injury: mechanisms and clinical importance","volume":"53","author":"Matute","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0635","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/08830189809043009","article-title":"TGF-\u03b2: a balancing act","volume":"16","author":"McCartney-Francis","year":"1998","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0640","unstructured":"MCCUBREY, J. A. 2018. Preclinical evaluation of the PI3K\/Akt\/mTOR pathway in animal models of multiple sclerosis."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0645","unstructured":"MCDONALD, D. B., ABU-ZAHRA, H., YOSHIDA, S. & BINDER, H. Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study. Seminars in Oncology, 1984. 19-22."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0650","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0655","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/897249","article-title":"Unraveling natalizumab effects on deregulated miR\u201017 expression in CD4+ T cells of patients with relapsing\u2010remitting multiple sclerosis","volume":"2014","author":"Meira","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0660","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.920408","article-title":"Serotonergic drug repurposing in multiple sclerosis: a new possibility for disease-modifying therapy","volume":"13","author":"Melnikov","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0665","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0670","doi-asserted-by":"crossref","unstructured":"MILLER, S. D., KARPUS, W. J. & DAVIDSON, T. S. 2010. Experimental autoimmune encephalomyelitis in the mouse. Current protocols in immunology, 88, 15.1. 1-15.1. 20.","DOI":"10.1002\/0471142735.im1501s88"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0675","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2020.00947","article-title":"Interleukin-17 in chronic inflammatory neurological diseases","volume":"11","author":"Milovanovic","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0680","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neuroscience.2008.05.025","article-title":"Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis","volume":"155","author":"Mitosek-Szewczyk","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0685","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.782599","article-title":"Synaptic loss in multiple sclerosis: a systematic review of human post-mortem studies","volume":"12","author":"M\u00f6ck","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0690","doi-asserted-by":"crossref","unstructured":"MOEZZI, D., DONG, Y., JAIN, R. W., LOZINSKI, B. M., GHORBANI, S., D\u2019MELLO, C. & WEE YONG, V. 2022. Expression of antioxidant enzymes in lesions of multiple sclerosis and its models. Scientific Reports, 12, 12761.","DOI":"10.1038\/s41598-022-16840-w"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0695","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ana.22521","article-title":"Multiple sclerosis normal\u2010appearing white matter: pathology\u2013imaging correlations","volume":"70","author":"Moll","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0700","first-page":"e466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol.: Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0705","doi-asserted-by":"crossref","DOI":"10.1177\/17590914221126367","article-title":"Cuprizone-induced demyelination in mouse brain is not due to depletion of copper","volume":"14","author":"Morgan","year":"2022","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103273","article-title":"Methylphenidate may improve mental fatigue in individuals with multiple sclerosis: a pilot clinical trial","volume":"56","author":"Natsheh","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0715","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-016-0688-8","article-title":"Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space","volume":"16","author":"Ntranos","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0725","doi-asserted-by":"crossref","first-page":"11718","DOI":"10.3390\/ijms130911718","article-title":"Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms","volume":"13","author":"O\u2019Gorman","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0730","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","article-title":"Oxidative stress in multiple sclerosis: Central and peripheral mode of action","volume":"277","author":"Ohl","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0735","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CMR.17.1.174-207.2004","article-title":"Theiler's virus infection: a model for multiple sclerosis","volume":"17","author":"Oleszak","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0740","first-page":"23","article-title":"Cytokine signaling in multiple sclerosis and its therapeutic applications","volume":"5","author":"Palle","year":"2017","journal-title":"Med. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0745","doi-asserted-by":"crossref","unstructured":"PANG, X.-W., CHEN, M., CHU, Y.-H., TANG, Y., QIN, C. & TIAN, D.-S. 2022. A stably established two-point injection of lysophosphatidylcholine-induced focal demyelination model in mice. JoVE (Journal of Visualized Experiments), e64059.","DOI":"10.3791\/64059-v"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0750","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/cimb45020094","article-title":"Multiple sclerosis: inflammatory and neuroglial aspects","volume":"45","author":"Papiri","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0755","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cells5020015","article-title":"Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches","volume":"5","author":"Park","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0760","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-014-0323-4","article-title":"Treatment of mood disorders in multiple sclerosis","volume":"17","author":"P\u00e9rez","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0770","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0775","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neubiorev.2014.10.004","article-title":"Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis","volume":"47","author":"Praet","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0780","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029249","article-title":"The evolving mechanisms of action of glatiramer acetate","volume":"9","author":"Prod\u2019Homme","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0785","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.654284","article-title":"Connecting neuroinflammation and neurodegeneration in multiple sclerosis: are oligodendrocyte precursor cells a nexus of disease?","volume":"15","author":"Psenicka","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0790","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-immunol-093019-124155","article-title":"The ins and outs of central nervous system inflammation\u2014lessons learned from multiple sclerosis","volume":"39","author":"Ramaglia","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0795","doi-asserted-by":"crossref","unstructured":"REICH, D. 2018. Lucchinetti CF and Calabresi PA. Multiple Sclerosis. New Engl J Med, 378, 169-180.","DOI":"10.1056\/NEJMra1401483"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0800","doi-asserted-by":"crossref","unstructured":"REVATHIDEVI, S. & MUNIRAJAN, A. K. Akt in cancer: Mediator and more. Seminars in cancer biology, 2019. Elsevier, 80-91.","DOI":"10.1016\/j.semcancer.2019.06.002"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0805","first-page":"28","article-title":"Disease-modifying therapies in multiple sclerosis: overview and treatment considerations","volume":"33","author":"Robertson","year":"2016","journal-title":"Fed. Pract."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0810","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","article-title":"The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment","volume":"122","author":"Robinson","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0815","first-page":"459","article-title":"Theiler's murine encephalomyelitis virus in nonbarrier rat colonies","volume":"55","author":"Rodrigues","year":"2005","journal-title":"Comp. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0820","doi-asserted-by":"crossref","unstructured":"RODR\u00cdGUEZ MUR\u00daA, S., FAREZ, M. F. & QUINTANA, F. J. 2022. The immune response in multiple sclerosis. Annual Review of Pathology: Mechanisms of Disease, 17, 121-139.","DOI":"10.1146\/annurev-pathol-052920-040318"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0825","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1177\/1352458520980366","article-title":"Cumulative effects of therapies on disability in relapsing multiple sclerosis","volume":"27","author":"Rollot","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0830","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neuron.2016.05.016","article-title":"Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism","volume":"91","author":"Saab","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0835","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0840","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fncel.2015.00077","article-title":"Alteration of synaptic connectivity of oligodendrocyte precursor cells following demyelination","volume":"9","author":"Sahel","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0845","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2012.01140.x","article-title":"T\u2010cell trafficking in the central nervous system","volume":"248","author":"Sallusto","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0850","doi-asserted-by":"crossref","unstructured":"SAN HERNANDEZ, A. M., SINGH, C., VALERO, D. J., NISAR, J., RAMIREZ, J. I. T., KOTHARI, K. K., ISOLA, S. & GORDON, D. K. 2020. Multiple sclerosis and serotonin: potential therapeutic applications. Cureus, 12.","DOI":"10.7759\/cureus.11293"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0855","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0860","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"6","author":"Schrempf","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0865","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2007.09.001","article-title":"The Frizzled family of unconventional G-protein-coupled receptors","volume":"28","author":"Schulte","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0870","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (tysabri)","volume":"31","author":"Selewski","year":"2010","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0875","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/glia.24148","article-title":"The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis","volume":"70","author":"Sen","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0880","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2015.08.005","article-title":"Experimental autoimmune encephalomyelitis and age-related correlations of NADPH oxidase, MMP-9, and cell adhesion molecules: The increased disease severity and blood\u2013brain barrier permeability in middle-aged mice","volume":"287","author":"Seo","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0885","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.expneurol.2012.02.018","article-title":"Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination","volume":"235","author":"Silvestroff","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0890","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0895","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.clinthera.2010.10.012","article-title":"Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis","volume":"32","author":"Siniscalchi","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0900","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","article-title":"Vitamin D and multiple sclerosis: a comprehensive review","volume":"7","author":"Sintzel","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0905","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0910","unstructured":"SOCIETY, N. M. S. 2024. Epidemiology [Online]. Available: https:\/\/www.nationalmssociety.org\/ [Accessed]."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0915","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40263-018-0489-5","article-title":"Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment","volume":"32","author":"Solaro","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0920","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.677879","article-title":"Antidepressants on multiple sclerosis: a review of in vitro and in vivo models","volume":"12","author":"Stamoula","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0930","doi-asserted-by":"crossref","unstructured":"STEINMAN, L. 2007. A brief history of TH17, the first major revision in the TH1\/TH2 hypothesis of T cell\u2013mediated tissue damage. Nature medicine, 13, 139-145.","DOI":"10.1038\/nm1551"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0935","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00702-014-1188-0","article-title":"The role of glutamate and its receptors in multiple sclerosis","volume":"121","author":"Stojanovic","year":"2014","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0940","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/glia.23606","article-title":"Inhibition of MAPK\/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases","volume":"67","author":"Suo","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0945","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fimmu.2016.00460","article-title":"Modulation of inflammatory responses by Wnt\/\u03b2-catenin signaling in dendritic cells: a novel immunotherapy target for autoimmunity and cancer","volume":"7","author":"Suryawanshi","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0950","doi-asserted-by":"crossref","unstructured":"TERRY, R. L., IFERGAN, I. & MILLER, S. D. 2016. Experimental autoimmune encephalomyelitis in mice. Multiple sclerosis: methods and protocols, 145-160.","DOI":"10.1007\/7651_2014_88"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0955","doi-asserted-by":"crossref","unstructured":"THEILER, M. 1937. Spontaneous encephalomyelitis of mice, a new virus disease. The Journal of experimental medicine, 65, 705-719.","DOI":"10.1084\/jem.65.5.705"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0960","doi-asserted-by":"crossref","unstructured":"TIZAOUI, K. 2018. Multiple sclerosis genetics: Results from meta-analyses of candidate-gene association studies. Cytokine, 106, 154-164.","DOI":"10.1016\/j.cyto.2017.10.024"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0965","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2008.01036.x","article-title":"The cuprizone model for demyelination","volume":"117","author":"Torkildsen","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0970","doi-asserted-by":"crossref","unstructured":"TSUNODA, I. & FUJINAMI, R. S. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer seminars in immunopathology, 2002. Springer, 105-125.","DOI":"10.1007\/s00281-002-0105-z"},{"key":"10.1016\/j.neuroscience.2024.12.029_b0975","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11481-009-9179-x","article-title":"Neuropathogenesis of Theiler\u2019s murine encephalomyelitis virus infection, an animal model for multiple sclerosis","volume":"5","author":"Tsunoda","year":"2010","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0980","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13550280802380563","article-title":"Theiler\u2019s murine encephalomyelitis virus attachment to the gastrointestinal tract is associated with sialic acid binding","volume":"15","author":"Tsunoda","year":"2009","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0985","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.574748","article-title":"Memantine for multiple sclerosis: a systematic review and meta-analysis of randomized trials","volume":"11","author":"Turalde","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0990","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s12035-018-1207-5","article-title":"Involvement of claudin-11 in disruption of blood-brain,-spinal cord, and-arachnoid barriers in multiple sclerosis","volume":"56","author":"Uchida","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b0995","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10571-017-0550-9","article-title":"Interactions between the canonical WNT\/beta-catenin pathway and PPAR gamma on neuroinflammation, demyelination, and remyelination in multiple sclerosis","volume":"38","author":"Vall\u00e9e","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1000","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1570159X15666170717120343","article-title":"Five decades of cuprizone, an updated model to replicate demyelinating diseases","volume":"17","author":"Vega-Riquer","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1005","doi-asserted-by":"crossref","unstructured":"VIDAL-JORDANA, A. 2018. New advances in disease-modifying therapies for relapsing and progressive forms of multiple sclerosis. Neurologic Clinics, 36, 173-183.","DOI":"10.1016\/j.ncl.2017.08.011"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1010","doi-asserted-by":"crossref","first-page":"10130","DOI":"10.1073\/pnas.1821306116","article-title":"Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis","volume":"116","author":"Voskuhl","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1015","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1024058","article-title":"Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis","volume":"15","author":"Voskuhl","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1020","doi-asserted-by":"crossref","unstructured":"WEHLING, M. 1997. Specific, nongenomic actions of steroid hormones. Annual review of physiology, 59, 365-393.","DOI":"10.1146\/annurev.physiol.59.1.365"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1025","doi-asserted-by":"crossref","unstructured":"WEKERLE, H. 2017. B cells in multiple sclerosis. Autoimmunity, 50, 57-60.","DOI":"10.1080\/08916934.2017.1281914"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1030","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1523\/JNEUROSCI.1862-17.2018","article-title":"Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells","volume":"38","author":"Welliver","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1035","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awt356","article-title":"Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden","volume":"137","author":"Westerlind","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1040","unstructured":"WHO 2023. Multiple sclerosis."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-016-0685-y","article-title":"Alemtuzumab for multiple sclerosis","volume":"16","author":"Willis","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/labinvest.3780235","article-title":"Multiple sclerosis: current pathophysiological concepts","volume":"81","author":"Wingerchuk","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1055","article-title":"Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/brain\/awh007","article-title":"Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study","volume":"127","author":"Wuerfel","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1065","doi-asserted-by":"crossref","first-page":"18083","DOI":"10.1038\/srep18083","article-title":"A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1* 1501 on risk of multiple sclerosis","volume":"5","author":"Xiao","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1075","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-018-0842-3","article-title":"Oligodendrocyte generation dynamics in multiple sclerosis","volume":"566","author":"Yeung","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2006.08.004","article-title":"5-HT1B receptors play a prominent role in the proliferation of T-lymphocytes","volume":"181","author":"Yin","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11481-012-9370-3","article-title":"Wnt signaling in the pathogenesis of multiple sclerosis-associated chronic pain","volume":"7","author":"Yuan","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch signaling: an emerging therapeutic target for cancer treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1100","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4103\/1673-5374.237109","article-title":"Role of nuclear factor \u03baB in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"13","author":"Yue","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cells9040843","article-title":"The cuprizone model: dos and do nots","volume":"9","author":"Zhan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1110","first-page":"1","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-023-01616-y","article-title":"Notch signaling pathway: a new target for neuropathic pain therapy","volume":"24","author":"Zhang","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.neuroscience.2024.12.029_b1120","doi-asserted-by":"crossref","first-page":"8160","DOI":"10.3390\/ijms25158160","article-title":"Epstein\u2013Barr viruses: their immune evasion strategies and implications for autoimmune diseases","volume":"25","author":"Zhao","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fimmu.2020.00391","article-title":"Nuclear factor \u03baB (NF-\u03baB)\u2013mediated inflammation in multiple sclerosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0074-7742(07)79024-4","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"79","author":"Ziemssen","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuroscience.2024.12.029_b1140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13024-024-00742-8","article-title":"The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells","volume":"19","author":"Zveik","year":"2024","journal-title":"Mol. Neurodegener."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224007358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224007358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:05:52Z","timestamp":1774260352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224007358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":228,"alternative-id":["S0306452224007358"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.12.029","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}